There is limited real-world data evaluating outcomes of glucagon-like peptide-1 receptor agonists (GLP1-RA) use in patients with moderate to advanced CKD. Here, emulating a clinical trial, the authors show that GLP1-RA use in patients with CKD is associated with lower rate of acute healthcare utilization, all-cause death and kidney events compared to DPP4i.
- Shuyao Zhang
- Fnu Sidra
- Ishak A. Mansi